BioCentury
ARTICLE | Company News

AlloVir, first to test ElevateBio's model, raises $120M ahead of Phase III

May 22, 2019 6:43 PM UTC

The first disclosed company that will test newly launched ElevateBio's cell and gene therapy model is antiviral treatment developer AlloVir, which revealed the companies' relationship along with a $120 million series B round on Wednesday.

ElevateBio LLC (Cambridge, Mass.) provides its portfolio companies with access to R&D, process development and cGMP manufacturing capabilities in a centralized setting (see "How ElevateBio Plans to Create Portfolio of Cell, Gene Therapy Newcos with $150M MPM, F2-Led Round")...

BCIQ Company Profiles

AlloVir Inc.